Abstract
Fragmentation patterns observed in plasma DNA reflect chromatin accessibility in contributing cells. Since DNA shed from cancer cells and blood cells may differ in fragmentation patterns, we investigated whether analysis of genomic positioning and nucleotide sequence at fragment ends can reveal the presence of tumor DNA in blood and aid cancer diagnostics. We analyzed whole genome sequencing data from >2700 plasma DNA samples including healthy individuals and patients with 11 different cancer types. We observed higher fractions of fragments with aberrantly positioned ends in patients with cancer, driven by contribution of tumor DNA into plasma. Genomewide analysis of fragment ends using machine learning showed overall area under the receiver operative characteristic curve of 0.96 for detection of cancer. Our findings remained robust with as few as 1 million fragments analyzed per sample, suggesting that analysis of fragment ends can become a cost-effective and accessible approach for cancer detection and monitoring.
One-sentence summary Analyzing the positioning and nucleotide sequence at fragment ends in plasma DNA may enable cancer diagnostics.
Competing Interest Statement
BRM, HM and MM are inventors on patent applications covering technologies described here including patent application number PCT/US20/41469, titled 'Methods of detecting disease and treatment response in cfDNA'. MM consults for AstraZeneca and Bristol Myers Squibb, and serves on the scientific advisory board of PetDx. BRM, TCC and MM have licensing relationships with Exact Sciences. All other authors declare that they have no competing interests.
Funding Statement
Supported by funding from the Ben and Catherine Ivy Foundation to MM, JMT and SC, from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award number 1U01CA243078-01A1 to MM and 1R01CA223481-01 to MM, and by a Stand Up To Cancer (SU2C) - Melanoma Research Alliance Melanoma Dream Team Translational Cancer Research Grant (#SU2C-AACR-DT0612) to JMT and PML. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research (AACR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Healthy volunteers were enrolled at the Translational Genomics Research Institute in Phoenix, AZ and blood samples were collected under protocol numbers 20142638, and 20181812, approved by Western Institutional Review Board (IRB). Blood and tissue samples from patients with melanoma were collected at Mayo Clinic in Scottsdale, AZ under protocol number 16-001453 and within a multi-center clinical trial (NCT02094872) under protocol number 20140190 approved by Western IRB. Blood samples from patients with breast cancer were collected at Mayo Clinic in Scottsdale, AZ under protocol number 14-006021, from patients with glioblastoma within a clinical trial (NCT02060890) at University of California in San Francisco, CA under protocol number 20141201 approved by Western IRB, and from patients with cholangiocarcinoma at Mayo Clinic in Scottsdale, AZ under protocol number 12-004713.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Plasma sequencing data generated for this study will be deposited in dbGaP once the manuscript is accepted for publication.
